Skip to content

Irritation and sensitization potential of novel dissolving microneedle patch : in vivo study

Irritation and sensitization potential of novel dissolving microneedle patch : in vivo study

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220127002
Enrollment
28
Registered
2022-01-27
Start date
2021-07-05
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer Dissolving microneedle Irritation Transdermal drug delivery

Interventions

n the induction phase, 28 healthy participants was applied by 600 nm, 1500nm nPatch, sodium lauryl sulfate patch(positive control) and petroleum patch(negative control) on their volar forearms for 24
Experimental Device
nPatch dissolving microneedle

Sponsors

Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University
Lead Sponsor
National Nanotechnology Center, National Science and Technology Development Agency
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male or female participants, aged 18-65. 2. Participants who are willing to join the project after receiving a detailed description of the project and signing a consent form for the study. 3. Participants can follow the testing method to follow up on treatment results throughout the study period and can report side effects that arise from the study immediately.

Exclusion criteria

Exclusion criteria: 1. Participants who are pregnant, breastfeeding, or planning to become pregnant. 2. Participants who had history of dermatologic conditions such as atopic dermatitis, psoriasis, vitiligo, melanoma, squamous cell carcinoma. 3. Participants who had history of Diabetes mellitus, porphyria, primary immunodeficiencies, HIV, anaphylaxis, asthma, generalized drug reaction, lymphoma, leukemia. 4. Participants had a history of connective tissue disease. 5. Participants who took immunosuppressants (Immunosuppressive agents). 6. Participants who had a history of allergic contact dermatitis to Tegaderm.

Design outcomes

Primary

MeasureTime frame
Skin irritation every visits after remove patches Irritation score,Skin irritation every visits after remove patches Skin imaging(photograph),skin irritation every visits after remove patches Transepidermal water loss

Secondary

MeasureTime frame
skin recovery every visits after remove patches Transepidermal water loss

Countries

Thailand

Contacts

Public ContactWareeporn Disphanurat

Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University, Thailand

dwareeporn@gmail.com029269435

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026